Cost-analysis of Treatment of Pediatrics Acute Lymphoblastic Leukemia based on ALL-BFM Protocol
Authors
Abstract:
Background Among all pediatric cancers acute lymphoblastic leukemia (ALL) is highly prevalent, butthe overall cost of ALL management is not well-known, there is a need to assess the Berlin-Frankfurt-Munster (BFM) protocol commonly used in ALL management in Iran. So, the aim of this study was to estimate direct and indirect costs of ALL treatment among children based on the ALL-BFM protocol from the societal perspective in Iran. Materials and Methods A retrospective study was conducted. All pediatric patients newly diagnosed with ALL and managed by the BFM protocol from 2010-2015 were included. Finally, total costs, including direct medical costs, direct non-medical costs and indirect costs were calculated. Results The total direct medical cost per patient for a complete treatment period was 15,026.6US dollars, the direct non-medical cost incurred was 1,688.9 USD and the indirect cost due to productivity loss was 932.3 USD. Conclusion Treatment of pediatrics ALL is less costly in Iran comparing other countries. So, physicians and policy makers and health care system administrators should devise an appropriate strategy to reduce the direct medical costs which have more economic burden special for hospitalization days and chemotherapy costs based on the findings.
similar resources
cost-analysis of treatment of pediatrics acute lymphoblastic leukemia based on all-bfm protocol
background among all pediatric cancers acute lymphoblastic leukemia (all) is highly prevalent, butthe overall cost of all management is not well-known, there is a need to assess the berlin-frankfurt-munster (bfm) protocol commonly used in all management in iran. so, the aim of this study was to estimate direct and indirect costs of all treatment among children based on the all-bfm protocol from...
full textIntensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991).
In The Netherlands from July 1988 to October 1991, children (0 to 16 years of age) with de novo acute lymphoblastic leukemia (ALL) were treated according to protocol ALL-7 of the Dutch Childhood Leukemia Study Group (DCLSG). In this protocol, chemotherapy and treatment stratification were identical to the ALL-BFM-86 protocol (Reiter et al, Blood 84:3122, 1994), but cranial irradiation was restr...
full textDETERMINATION OF A SHARED EPITOPE ON CELLS FROM ACUTE MYELOGENIC LEUKEMIA (AML) AND T-ACUTE LYMPHOBLASTIC LEUKEMIA ( T-ALL)
Two IgM monoclonal antibodies (MAb) with strong reactivity for granulocytes and to a lesser extent for lurkat cell lines were established by immunizing BALBI c mice with a histiocytic cell line (UY37). These two MAbs (designated as 6C9 and 4C4) reacted with blast cells of T-acute lymphoblastic leukemia (T-ALL) and acute myelogenous leukemia (AML) patients as well as leukemic cells from pat...
full textImmunologic subclassification of acute lymphoblastic leukemia in childhood and prognosis (modified BFM protocol).
Acute lymphoblastic leukemias (ALLs) in childhood are clonal proliferations of lymphoid cells. It is now possible precisely to define stages of human lymphocyte differentiation using more traditional cell markers such as surface membrane immunoglobulin (SIg), sheep erythrocyte receptor (E), and cytochemical stains or highly specific monoclonal antibodies. The application of these immunologic me...
full textClinical experiences with a modified BFM protocol in childhood acute lymphoblastic leukemia.
The most important problem in current therapy of childhood acute lymphoblastic leukemia (ALL) is a failure in over one-half of patients. We were unable to increase the failure-free survival of children with high risk ALL by a ten-drug regimen (modified LSA 2 L 2) above 30% at 6 years [1].
full textMy Resources
Journal title
volume 4 issue 9
pages 3381- 3389
publication date 2016-09-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023